VanEck Pharmaceutical ETF
PPH
43 hedge funds and large institutions have $129M invested in VanEck Pharmaceutical ETF in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 5 closing their positions.
132% more capital invested
Capital invested by funds: $55.8M → $129M (+$73.4M)
63.61% more ownership
Funds ownership: 31.34% → 94.95% (+64%)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more funds holding
Funds holding: 41 → 43 (+2)
2% more call options, than puts
Call options by funds: $819K | Put options by funds: $802K
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$41.3M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$22.9M |
| 3 |
Goldman Sachs
New York
|
+$11.5M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$8.58M |
| 5 |
JP Morgan Chase
New York
|
+$5.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WWM
Western Wealth Management
Golden,
Colorado
|
-$8.37M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.32M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.24M |
| 4 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$802K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$727K |
PPH Hedge Fund Activity: Q3 2019 in Review
43 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2019, worth a combined $129M — up 132% from $55.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PPH positions and 5 closed out — a net gain of 2 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Bank of America, adding an estimated $41.3M. The largest seller was Western Wealth Management, exiting entirely with an estimated $8.37M sold.
- 43 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2019, up from 41 in Q2 2019.
- Funds reported $129M of VanEck Pharmaceutical ETF stock for Q3 2019, up 132% quarter-over-quarter.
- 7 funds opened new VanEck Pharmaceutical ETF positions in Q3 2019 and 5 closed out, a net change of +2 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2019 was Bank of America, an estimated $41.3M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2019 was Western Wealth Management, an estimated $8.37M sold.
Based on aggregated 13F filings for Q3 2019.